Development of nonviral allogeneic CAR-based therapies that can effectively target solid tumors are at the forefront of cancer treatment innovation. In this webinar, Dr. Devon Shedlock of Poseida Therapeutics shares the company's approach to manufacturing allogeneic CAR-T therapy and discusses the importance of stemness for effectiveness in the clinic.

Watch the talk to learn about:

• How nonviral methods of gene delivery can produce safe and effective cell therapy products
• The importance of stemness in developing effective CAR-T therapies
• An iterative approach to developing products and growing a robust pipeline of cell therapies